NCT03232671

Brief Summary

Evaluating the additional value of Macrophage Migration Inhibitory factor (MIF) in cardiovascular diseases when assessed in clinical routine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2016

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

July 25, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 28, 2017

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2020

Completed
Last Updated

November 4, 2022

Status Verified

November 1, 2022

Enrollment Period

4.1 years

First QC Date

July 25, 2017

Last Update Submit

November 3, 2022

Conditions

Heart Diseases

Outcome Measures

Primary Outcomes (1)

  • 180 days mortality

    180 days

Interventions

MIF ELISADIAGNOSTIC_TEST

Blood sample

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients presenting with symptoms of heart failure.

You may qualify if:

  • All patients presenting with symptoms of heart failure to the West-German Heart and Vascular Center according to the definition of the ESC 2016.
  • Patients fulfilling criteria for the diagnosis of HFrEF
  • Patients fulfilling criteria for the diagnosis of HFpEF
  • Patients fulfilling criteria for the diagnosis of HFmrEF
  • Patients presenting with dyspnea according to the NYHA classification I-IV, elevated BNP/NT-proBNP levels and echocardiographic findings of heart failure.

You may not qualify if:

  • Age \< 18 years
  • Patients with symptoms of heart failure without fulfilling the criteria of the ESC guidelines 2016
  • Denial to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Essen

Essen, North Rhine-Westphalia, 45147, Germany

Location

Related Publications (1)

  • Luedike P, Alatzides G, Papathanasiou M, Heisler M, Pohl J, Lehmann N, Rassaf T. Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF). Eur J Med Res. 2018 May 4;23(1):22. doi: 10.1186/s40001-018-0321-1.

    PMID: 29728137DERIVED

MeSH Terms

Conditions

Heart Diseases

Condition Hierarchy (Ancestors)

Cardiovascular Diseases

Study Officials

  • Peter Lüdike, M.D.

    University Hospital of Essen, Department of Cardiology and Vascular medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

July 25, 2017

First Posted

July 28, 2017

Study Start

March 1, 2016

Primary Completion

April 1, 2020

Study Completion

September 1, 2020

Last Updated

November 4, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations

DE(1)